Limits...
Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats.

Vafaee F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK - Neural Regen Res (2012)

Bottom Line: The immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties.Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia.These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.

View Article: PubMed Central - PubMed

Affiliation: Neuroscience Research Center, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

ABSTRACT
Anti-inflammatory and anti-oxidant agents can alleviate ischemic cerebral injury. The immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties. Therefore, we hypothesized that Setarud will have a neuroprotective effect against ischemic cerebral injury. To validate this hypothesis, rats were intraperitoneally administered with 0.66 mL/kg Setarud for 30 minutes after middle cerebral artery occlusion. Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia. Transmission electron microscopy and hematoxylin-eosin staining results showed that Setarud could alleviate the degenerative changes in cortical neurons of rats with cerebral ischemia. The inclined plate test and prehensile test showed that Setarud could significantly improve the motor function of rats with cerebral ischemia. These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.

No MeSH data available.


Related in: MedlinePlus

Effect of Setarud on infarct volume of rats subjected to middle cerebral artery occlusion.Data are expressed as mean ± SEM (n = 4 rats/group, aP < 0.05, vs. vehicle group). The data were analyzed with one-way analysis of variance followed by post-hoc Tukey's test. IMOD: Immunomodulatory drug.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4281408&req=5

Figure 1: Effect of Setarud on infarct volume of rats subjected to middle cerebral artery occlusion.Data are expressed as mean ± SEM (n = 4 rats/group, aP < 0.05, vs. vehicle group). The data were analyzed with one-way analysis of variance followed by post-hoc Tukey's test. IMOD: Immunomodulatory drug.

Mentions: Setarud injection at 30 minutes after MCAO significantly reduced brain infarct volume in rats with cerebral ischemia/ reperfusion (n = 4 rats/group; P < 0.05; Figures 1, 2).


Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats.

Vafaee F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK - Neural Regen Res (2012)

Effect of Setarud on infarct volume of rats subjected to middle cerebral artery occlusion.Data are expressed as mean ± SEM (n = 4 rats/group, aP < 0.05, vs. vehicle group). The data were analyzed with one-way analysis of variance followed by post-hoc Tukey's test. IMOD: Immunomodulatory drug.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4281408&req=5

Figure 1: Effect of Setarud on infarct volume of rats subjected to middle cerebral artery occlusion.Data are expressed as mean ± SEM (n = 4 rats/group, aP < 0.05, vs. vehicle group). The data were analyzed with one-way analysis of variance followed by post-hoc Tukey's test. IMOD: Immunomodulatory drug.
Mentions: Setarud injection at 30 minutes after MCAO significantly reduced brain infarct volume in rats with cerebral ischemia/ reperfusion (n = 4 rats/group; P < 0.05; Figures 1, 2).

Bottom Line: The immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties.Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia.These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.

View Article: PubMed Central - PubMed

Affiliation: Neuroscience Research Center, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

ABSTRACT
Anti-inflammatory and anti-oxidant agents can alleviate ischemic cerebral injury. The immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties. Therefore, we hypothesized that Setarud will have a neuroprotective effect against ischemic cerebral injury. To validate this hypothesis, rats were intraperitoneally administered with 0.66 mL/kg Setarud for 30 minutes after middle cerebral artery occlusion. Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia. Transmission electron microscopy and hematoxylin-eosin staining results showed that Setarud could alleviate the degenerative changes in cortical neurons of rats with cerebral ischemia. The inclined plate test and prehensile test showed that Setarud could significantly improve the motor function of rats with cerebral ischemia. These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.

No MeSH data available.


Related in: MedlinePlus